Redefining the primary objective of phase i oncology trials

Nature Reviews Clinical Oncology

Volumn 11, Issue 9, 2014, Pages 503-504

  Ratain, Mark J ^a  

^a University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; CERITINIB; CISPLATIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TEMSIROLIMUS; VINCA ALKALOID; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; CARDIOTOXICITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CANCER; KIDNEY DISEASE; LUNG CANCER; MAXIMUM TOLERATED DOSE; NEUROPATHY; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; ARTICLE; DRUG APPROVAL; METHODOLOGY; MOLECULARLY TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG APPROVAL; HUMANS; MOLECULAR TARGETED THERAPY; RESEARCH DESIGN;

EID: 84906840020     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.135     Document Type: Short Survey

References (10)

1. Paoletti, X. et al. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. Eur. J. Cancer 50, 2050-2056 (2014).
2. Dose-response information to support drug registration E4. ICH Harmonised Tripartite Guidline [online], http://www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Efficacy/E4/Step4/E4-Guideline.pdf (1994).
3. Atkins, M. B. et al. Randomized phase II study of multiple dose levels of CCI 779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004).
4. Jonat, W. et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 32A, 404-412 (1996).
5. Shaw, A. T. et al. Ceritinib in ALK-rearranged non small cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014).
6. Ceritinib drug safety data. FDA Center for Drug Evaluation and Research [online], http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/ 205755Orig1s000SumR.pdf (2014).
7. Ceritinib drug safety data summary review. FDA Center for Drug Evaluation and Research [online], http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/ 205755Orig1s000ClinPharmR.pdf (2014).
8. Ceritinib clinical investigator financial disclosure review template. FDA Center for Drug Evaluation and Research [online], http://www.accessdata. fda.gov/drugsatfda-docs/nda/2014/205755Orig1s000MedR.pdf (2014).
9. Szmulewitz, R. Z. & Ratain, M. J. Playing Russian roulette with tyrosine kinase inhibitors. Clin. Pharmacol. Ther. 93, 242-244 (2013).
10. Kremer, J. M. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP 690, 550 versus placebo. Arthritis Rheum. 60, 1895-1905 (2009